

# Natural Occurrence of 11-*O*-Acetylbambelline and 11-*O*-Acetyl-1,2- $\beta$ -epoxybambelline in *Crinum latifolium*: Immuno-regulant Alkaloids<sup>3</sup>

Shibnath Ghosal<sup>1,2</sup>, Potharaju H. Rao<sup>1</sup>, and Kulwant S. Saini<sup>1</sup>

Received: January 27, 1985; accepted: April 25, 1985.

The occurrence of two new bioactive 5,10b-ethanophenanthridine alkaloids, 11-*O*-acetylbambelline (**1**) and 11-*O*-acetyl-1,2- $\beta$ -epoxybambelline (**2**), in the resting bulbs of *Crinum latifolium* Linn. (Amaryllidaceae) is reported. The structures of the two alkaloids have been established on the basis of chemical and spectral evidence. Immunobiological screening data would seem to suggest a combination (1 : 1) of **1** and **2** to act as a potential immunoregulant.


This investigation was aimed at delving into the catabolic sequence of bambelline and 1,2- $\beta$ -epoxybambelline, occurring in a ratio of approximately 3 : 1 (**1**) in sev-

eral *Crinum* species (**2**) during pre- and post-flowering stages covering a span of approximately 8 weeks. In the resting bulbs of *C. latifolium*, the two alkaloids are vicariously represented by their respective 11-*O*-acetyl derivatives.

The mixture of alkaloids (0.12 g) from the silica gel column chromatography of 'fraction B<sub>3</sub>' (**3**), obtained from the resting bulbs of the title species (collected during January 1980, '81, '82) (1 kg wet weight, each), was taken up in MeOH-H<sub>2</sub>O (90 : 10, 5 ml). The solution was subjected to semi-preparative H.P.L.C. [Spectra Physics model 8000, UV detector (254 nm); RP-8 column (25 × 0.8 cm, i. d.); MeOH-H<sub>2</sub>O

(90 : 10) as the mobile phase, flow rate 8 ml/min]. Compounds **2** and **1** were obtained in succession (*t<sub>R</sub>* 406 and 488 s, respectively). Analytical HPLC [Waters Associates model 440, 6000 A/U 6K; 254 nm/0.1 aufs; RP-18 column; MeOH-H<sub>2</sub>O (80 : 20) mobile phase, flow rate 1 ml/min] of the mixture ('fraction B<sub>3</sub>' from the resting bulbs) showed only traces of bambelline (*t<sub>R</sub>* 390 s) and 1,2- $\beta$ -epoxybambelline (*t<sub>R</sub>* 300 s).

**11-*O*-Acetylbambelline (1)**. This compound crystallized from MeOH-AcMe as colourless prisms (36 mg, yield ca. 0.003 %), mp 232-235 °C,  $\lambda_{\text{max}}^{\text{MeOH}}$  nm (log  $\epsilon$ ) 240 sh (3.0), 290 (3.08);  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup> 1730, 1612, 1208, 1070, 938;  $\delta_{\text{H}}$  (CDCl<sub>3</sub>) 6.55 (1H, d, *J* = 10 Hz, H-1), 6.40 (1H, s, H-10), 5.92 (1H, dd, *J* = 10, 5 Hz, H-2), 5.81 (2H, s, OCH<sub>2</sub>O), 5.18 (1H, dd, *J* = 4, 8 Hz, H-11), 4.28 (1H, d, *J* = 17 Hz, H $\beta$ -6), 4.02 (1H, m, H-3), 3.96 (3H, s, C<sub>7</sub>-OMe), 3.75 (1H, d, *J* = 17 Hz, H $\alpha$ -6), 3.33 (3H, s, C<sub>3</sub>-OMe),



**Table I.** Effects of **1** and **2** on Mouse Splenic Lymphocytes<sup>a</sup>, Peritoneal Macrophage<sup>b</sup>, and Spleen Weight.

Compound	Stimulation Index <sup>c,d</sup>			Macrophage <sup>e</sup>			Spleen weight <sup>e</sup>	
	qs	4 days of tumor growth	12 days of tumor growth	normal × 10 <sup>6</sup>	RN (elicited) × 10 <sup>6</sup> 48 h	72 h	normal in mg	treated in mg
Concanavalin A	7.95 ±0.43	7.87 ±0.50	2.53 ±0.66					
<b>1</b>	3.11 ±0.72	2.94 ±0.64	2.38 ±0.58		2.55	4.62		191.6
<b>2</b>	5.05 ±1.75	4.98 ±0.77	3.38 ±0.28		2.60	4.71		248.4
<b>1 + 2</b> (1 : 1)	6.46 ±0.86	6.74 ±0.24	4.55 ±0.21		2.93	14.97		348.95
				2.42			198.7	

<sup>a,b</sup> protocols as described before (8, 9). <sup>c</sup> n = 6. <sup>d</sup> 5  $\mu$ g/ml in phosphate buffered saline (PBS, pH 7.2); mean  $\pm$  s. d. <sup>e</sup> n = 14 [Swiss mice (adult male) inoculated intraperitoneally (i. p.) with **1** (50  $\mu$ g) + **2** (50  $\mu$ g), in PBS; peritoneal cells were counted after 48 and 72 h; spleen weight were recorded]. <sup>f</sup> Sarcoma 180 ascites tumor cells; qs, quiescent state (normal mice).

<sup>1</sup> Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutics, Banaras Hindu University, Varanasi-221005, India.

<sup>2</sup> Correspondence.

<sup>3</sup> Part 16 in the Series "Chemical Constituents of Amaryllidaceae". For Part 15 see ref. (8).

obtained in succession (*t<sub>R</sub>* 406 and 488 s, respectively). Analytical HPLC [Waters Associates model 440, 6000 A/U 6K; 254 nm/0.1 aufs; RP-18 column; MeOH-H<sub>2</sub>O (80 : 20) mobile phase, flow rate 1 ml/min] of the mixture ('fraction B<sub>3</sub>'

**11-*O*-Acetyl-1,2- $\beta$ -epoxybambelline (2)**. This compound crystallized from AcMe as colourless micro-crystals (14 mg, yield ca. 0.001 %), mp 201-204 °C;  $\lambda_{\text{max}}^{\text{MeOH}}$  240 sh (2.99), 286 (3.04);  $\nu_{\text{max}}^{\text{KBr}}$  1728, 1622, 1209, 940;  $\delta_{\text{H}}$

3.2–2.8 (2H, m, H,H-12), 1.81 (3H, s, strongly shielded 11-*O*-Ac), 1.7–1.4 (2H, m, H,H-4); *m/z* 373 ( $M^+$ , 100%), 299 (22), 247 (14), 211 (12) (Found: C, 64.1; H, 6.32; N, 3.33.  $C_{20}H_{23}NO_6$  requires C, 64.34; H, 6.16; N, 3.75%). Deacetylation of **1** with NaOMe in MeOH (**4**) gave ambelline **3** (mp, mmp, co-TLC, IR).

*11-O-Acetyl-1,2-β-epoxyambelline*

(**2**). This compound crystallized from AcMe as colourless micro-crystals (14 mg, yield ca. 0.001%), mp 201–204 °C;  $\lambda_{max}^{MeOH}$  240 sh (2.99), 286 (3.04);  $\nu_{max}^{KBr}$  1728, 1622, 1209, 940;  $\delta_H$  ( $CDCl_3$ ) 6.59 (1H, s, H-10), 5.90 (2H, s,  $OCH_2O$ ), 5.16 (1H, dd,  $J = 4, 8$  Hz, H-11), 4.30 (1H, d,  $J = 17$  Hz,  $H_{\beta}$ -6), 4.04 (3H, s,  $C_7$ -OMe), 4.0 (1H, br. m, H-3), 3.74 (1H, d,  $J = 17$  Hz,  $H_{\alpha}$ -6), 3.39 (3H, s,  $C_3$ -OMe), 3.3–2.85 (2H, m, H,H-12), 1.79 (3H, s, OAc), 1.7–1.4 (2H, m, H,H-4) [Found (by accurate mass mea-

surement)  $M$ , 389.147.  $C_{20}H_{23}NO_7$  requires  $M$ , 389.147]. On deacylation, as before, **2** gave 1,2-β-epoxyambelline (**4**) (**1**) (mp, mmp, co-TLC, MS).

To our knowledge, this is the first demonstration of the natural occurrence of **1** and **2**. *O*-Acetylation of *Amaryllidaceae* alkaloids, seems to be a common biochemical process of transformation in the *Crinum* species. Thus, a number of *O*-acetyl derivatives, viz. 1-*O*-acetyl and 1,2-*O*-diacetyllycorine, 3-*O*-acetylcrinine, 3-*O*-acetylhamayne, were previously reported from this genus (5, 6, 7).

#### Acknowledgement

We are indebted to Dr. U. Chattopadhyay, division of Tumor Immunobiology, Chittaranjan Cancer Research Centre, Calcutta, for the biological screening. PR and KSS thank the University grants Commission, New Delhi, for research fellowships.

#### References

- (1) Ghosal, S., Saini, K. S., Arora, V. K. (1984) *J. Chem. Res. (S)* 232–233.
- (2) Ghosal, S., Saini, K. S., Razdan, S. (1985) *Phytochemistry* 24, in the press.
- (3) Ghosal, S., Saini, K. S., Frahm, A. W. (1983) *Phytochemistry* 22, 2305–2309.
- (4) Ghosal, S., Saini, K. S. (1984) *J. Chem. Res. (S)* 110; (M) 965–975.
- (5) Ghosal, S., Rao, P. H., Jaiswal, D. K., Kumar, Y., Frahm, A. W. (1981) *Phytochemistry* 20, 2003–2007.
- (6) Kobayashi, S., Tokumoto, T., Kihara, M., Imakura, Y., Shingu, T., Taira, Z. (1984) *Chem. Pharm. Bull. (Tokyo)* 32, 3015–3022.
- (7) Tsuda, Y., Kashiwaba, N., Kumar, V. (1984) *Chem. Pharm. Bull. (Tokyo)* 32, 3023–3027.
- (8) Chattopadhyay, U., Chaudhuri, L., Das, S., Kumar, Y., Ghosal, S. (1984) *Pharmazie* 39, 855–856.
- (9) Chattopadhyay, U., Chaudhuri, L., Das, S., Chattopadhyay, S., Ghosal S. (1985) *Pharmazie* 40, in the press.